Durant J R, Norgard M J, Murad T M, Bartolucci A A, Langford K H
Ann Intern Med. 1979 Feb;90(2):191-4. doi: 10.7326/0003-4819-90-2-191.
Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy. This was lethal in seven patients, four of whom had no evidence of tumor at autopsy. Presenting symptoms were either the insidious onset of cough and dyspnea or the sudden onset of respiratory failure. Physical findings were unremarkable. Chest roentgenogram usually showed interstitial infiltrates. Pulmonary function studies showed resting hypoxia with diffusion and restrictive defects. This complication of therapy does not appear to be dose related and may be made more likely by the concomitant administration of cyclophosphamide. Prednisone therapy did not benefit most patients. The literature and the implications of the use of BCNU alone or in combination are reviewed.
10名患者在接受双氯乙基亚硝脲（BCNU）治疗恶性肿瘤后出现了肺纤维化。这在7名患者中是致命的，其中4名患者在尸检时没有肿瘤证据。主要症状要么是咳嗽和呼吸困难的隐匿性发作，要么是呼吸衰竭的突然发作。体格检查结果无异常。胸部X线片通常显示间质浸润。肺功能研究显示静息性低氧血症，伴有弥散和限制性缺陷。这种治疗并发症似乎与剂量无关，同时使用环磷酰胺可能会增加其发生的可能性。泼尼松治疗对大多数患者无益。本文回顾了单独使用或联合使用BCNU的文献及相关影响。
